Bayesian Phase Iii Trials
Bayesian Phase III Trials is a type of confirmatory clinical trial design that employs Bayesian statistical methods to dynamically update evidence about treatment efficacy and safety during the trial, distinguishing it from traditional frequentist Phase III trials by incorporating prior knowledge and enabling probabilistic decision-making about treatment success or futility.
33
Publications
856
Citations
131
Authors
96
Institutions
Publications per year
2017–2026
14
Parents
33
Seamlessly Expanding a Randomized Phase II Trial to Phase III
Lurdes Y. T. Inoue, Peter F. Thall, Donald A. Berry · Biometrics · 2002 · 130 citations
1–5 of 33
131
3
h-index
3
h-index
2
h-index
2
h-index
The University of Texas MD Anderson Cancer Center, United States
2 publications · 147 citations
2
h-index
1–5 of 131
96
Novartis (Switzerland)
Basel, Switzerland
6 h-index
21 publications
444 citations
Cancer Research UK Clinical Trials Unit
Birmingham, United Kingdom
3 h-index
6 publications
196 citations

University of Birmingham
Birmingham, United Kingdom
3 h-index
5 publications
152 citations
Inserm
Paris, France
2 h-index
5 publications
101 citations
Eli Lilly (United States)
Indianapolis, United States
2 h-index
4 publications
126 citations
Délégation Paris 7
Bagnolet, France
2 h-index
5 publications
101 citations
Duke University
Durham, United States
2 h-index
2 publications
55 citations
Pfizer (United States)
New York, United States
2 h-index
2 publications
47 citations
1–8 of 96
8 publications · 208 citations
8
h-index
3 publications · 56 citations
3
h-index
2 publications · 54 citations
2
h-index
2 publications · 26 citations
2
h-index
2 publications · 154 citations
2
h-index
1–5